| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $84.9K | 0.00% | 105.80K | +322% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a APRE trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Pamakcu RifatDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Henneman John Bell IiiDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Bizzari Jean-PierreDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Peters RichardDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Grissinger Michael J.Director | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Seizinger Bernd R.Director | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Gruia GabrielaDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Jun 15, 2026 | Duey MarcDirector | Stock Award(Grant) at price 0.00 per share. | 3.1K | — |
| Mar 11, 2026 | Hamill John PChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 10.1K | — |
| Mar 11, 2026 | Gilad OrenChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 20.2K | — |
| Jan 29, 2026 | Hamill John PChief Financial Officer | Purchase at price 0.89 per share. | 5.7K | $5.07K |
| Jan 29, 2026 | Gilad OrenChief Executive Officer | Purchase at price 0.89 per share. | 28.1K | $25.01K |
| Dec 9, 2025 | Hamill John PChief Financial Officer | Purchase at price 0.91 per share. | 5K | $4.56K |
| Dec 9, 2025 | Duey MarcDirector | Purchase at price 0.91 per share. | 21.5K | $19.57K |
| Jun 4, 2025 | Pamakcu RifatDirector | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Jun 4, 2025 | Henneman John Bell IiiDirector | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Jun 4, 2025 | Bizzari Jean-PierreDirector | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Jun 4, 2025 | Peters RichardDirector | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Jun 4, 2025 | Grissinger Michael J.Director | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Jun 4, 2025 | Seizinger Bernd R.Director | Stock Award(Grant) at price 0.00 per share. | 1K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -6.7 | 15.2 | -16.8 | 4.8 | 11.6 | -10.2 | -22.7 | 29.0 | -6.3 | -20.0 | −29.7% | ||
| 2025 | 18.8 | -35.2 | -19.5 | -14.7 | 0.0 | -2.9 | 0.6 | -7.9 | -5.8 | -5.1 | -10.0 | -32.3 | −74.1% |
| 2024 | 10.0 | 63.6 | -20.9 | -23.8 | -6.5 | -14.7 | -11.1 | -5.3 | -19.8 | 42.2 | -25.8 | 13.4 | −30.0% |
| 2023 | 51.4 | -48.8 | -13.5 | -10.7 | -2.9 | -18.2 | -1.6 | 19.4 | 12.6 | -19.4 | 8.3 | 29.1 | −29.0% |
| 2022 | -27.2 | -16.7 | 6.9 | -21.5 | -42.6 | -10.5 | 28.0 | -17.3 | -18.1 | 3.1 | -38.1 | -20.2 | −88.5% |
| 2021 | 12.2 | 9.2 | -15.4 | -8.0 | -10.0 | 15.6 | -13.3 | 9.2 | 10.6 | -3.1 | -18.4 | -29.0 | −41.7% |
| 2020 | -16.5 | -10.5 | 1.3 | -8.5 | -15.5 | 44.4 | -29.3 | -1.2 | -11.2 | -9.4 | 15.7 | -80.5 | −89.3% |
| 2019 | 4.3 | 82.2 | +90.0% |
Buy / hold / sell counts
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.